Stryker Corporation (SYK) Earnings Call Transcripts

Stryker Corporation's Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, Stryker Corporation (SYK:US) reported strong organic sales growth of 9%, driven by robust performances in MedSurg, Neurotechnology, and Orthopedics. Adjusted EPS grew by 17.9% to $3.69, reflecting improved gross margins and operational execution. Management narrowed its full-year guidance, now expecting organic net sales growth between 8.3% and 9.3% and adjusted EPS in the range of $14.95 to $15.10, signaling confidence in a strong second half despite ongoing supply disruptions in the Peripheral Vascular segment.

Reported metrics

Guidance from management

Management expects organic net sales growth for the full year to be in the range of 8.3% to 9.3% and adjusted EPS to be between $14.95 and $15.10, reflecting confidence in the second half despite supply chain challenges.

What management said

No. I think, again, like we said before, we're going to see that happening at different paces and different times. And part of it is, as Kevin said, the ramping up of production for those capital products that we can get those out the door. So I think you're going to see kind of a steady cadence across both.

Travis, in terms of U.S. hips, nothing that we would point to in terms of major share shifts or changes there. I think the one thing I would point out is, again, the delivery of the number this year was against a pretty large prior year comparable. So we had 8% growth last year in that space. So just -- it's really just a comparable. I think as we look at any of our numbers across Orthopedics, we always say one quart...

What analysts pressed on

Analysts expressed concerns regarding the ability to meet the upper end of the guidance range, particularly in light of the supply disruptions in the Peripheral Vascular segment. There were questions about the underlying growth trends versus catch-up from prior quarters and the stability of procedural volumes going forward.

Main topics on the call

• Organic Sales Growth — Stryker achieved organic sales growth of 9% in Q2 2026, with high single-digit growth from MedSurg and Neurotechnology. Management noted, "We delivered strong organic sales growth of 9% including high single-digit growth...
• Peripheral Vascular Supply Disruption — Management acknowledged significant supply disruptions in the Peripheral Vascular business, leading to back orders and lost sales. They stated, "The supply disruption resulted in a meaningful back order situation with lo...
• Adjusted EPS Growth — Stryker reported adjusted EPS of $3.69, up 17.9% year-over-year, driven by strong sales growth and operational excellence. This reflects a solid recovery from the previous quarter's challenges.
• Narrowed Guidance — Management narrowed its full-year guidance, expecting organic net sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10. They expressed confidence, stating, "We remain confident in the long-term outlook for p...

Read the full Stryker Corporation transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 53 Stryker Corporation earnings call transcripts on record, spanning January 28, 2020 to July 30, 2026. Based on this history, Stryker Corporation reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SYK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

53

First call

January 28, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly